PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29599338-2	2018	Here we investigated the different susceptibility of glutamine-independent and glutamine-dependent non-small cell lung cancer (NSCLC) to treatment with tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor gamitrinib-triphenylphosphonium (G-TPP).	gamitrinib-triphenylphosphonium	222-253	TNF receptor associated protein 1	Homo sapiens	152-203	
29599338-2	2018	Here we investigated the different susceptibility of glutamine-independent and glutamine-dependent non-small cell lung cancer (NSCLC) to treatment with tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor gamitrinib-triphenylphosphonium (G-TPP).	gamitrinib-triphenylphosphonium	222-253	TNF receptor associated protein 1	Homo sapiens	205-210	
34539842-5	2021	TRAP1 inhibitor Gamitrinib triphenylphosphonium (G-TPP) and shRNA were used in the present study to suppress the function of this molecule in glioblastoma multiforme (GBM) cell lines.	gamitrinib-triphenylphosphonium	16-47	TNF receptor associated protein 1	Homo sapiens	0-5	
34539842-5	2021	TRAP1 inhibitor Gamitrinib triphenylphosphonium (G-TPP) and shRNA were used in the present study to suppress the function of this molecule in glioblastoma multiforme (GBM) cell lines.	gamitrinib-triphenylphosphonium	49-54	TNF receptor associated protein 1	Homo sapiens	0-5